TABLE 3.
Univariate and multivariate analyses of the effect of GAL3 expression on recurrence‐free survival (RFS)
| Factors | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p‐value | HR | 95% CI | p‐value | |
| GAL3 expression | ||||||
| High vs. low | 2.542 | 1.468–4.399 | <0.001 | 1.923 | 1.083–3.413 | 0.026 |
| Age, years | ||||||
| ≥60 vs. <60 | 1.062 | 0.634–1.780 | 0.818 | Not included | ||
| Sex | ||||||
| Male vs. female | 1.724 | 1.045–2.846 | 0.33 | Not included | ||
| Smoking status | ||||||
| Smoker vs. never smoker | 0.682 | 0.410–1.133 | 0.139 | Not included | ||
| Histological type | ||||||
| AD vs. non‐AD | 0.286 | 0.135–0.604 | < 0.001 | 0.392 | 0.179–0.859 | 0.019 |
| p‐TNM stage | ||||||
| Stage III vs. stage II | 2.422 | 1.287–4.557 | 0.006 | 2.004 | 1.055–3.804 | 0.034 |
| Chemotherapeutic regimen | ||||||
| CDDP vs. CBDCA based | 0.84 | 0.480–1.468 | 0.54 | Not included | ||
| Number of treatment cycles | ||||||
| 3–4 vs. 1–2 | 0.934 | 0.444–1.965 | 0.858 | Not included | ||
Note: All analyses were performed using Cox proportional hazard regression.
Abbreviations: CBDCA, carboplatin; CDDP, cisplatin; 95% CI, 95% confidence interval; HR, hazard ratio.